Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stinging insect allergy.

David B K Golden1

  • 1Johns Hopkins University School of Medicine, Asthma and Allergy Center, Baltimore, Maryland 21224, USA.

American Family Physician
|June 27, 2003
PubMed
Summary
This summary is machine-generated.

Systemic allergic reactions to insect stings affect 1-3% of people. Venom immunotherapy is highly effective (98%) for preventing severe reactions in at-risk individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics and pharmacodynamics of AQST-109 sublingual film in oral allergy syndrome: A phase 2 study.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Stability of epinephrine nasal spray under room temperature, freeze-thaw, and extreme temperature conditions.

The journal of allergy and clinical immunology. In practice·2026
Same author

2025 Inborn errors of immunity practice parameter: Guidance from the Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI) and the Clinical Immunology Society (CIS).

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Venom Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same author

Guidelines and shared decision-making for disruptive innovations in allergy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Non-injectable versus injectable epinephrine treatment thresholds for acute allergic reactions in the community.

The journal of allergy and clinical immunology. In practice·2026
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles

Area of Science:

  • Allergy and Immunology
  • Insect Sting Reactions
  • Anaphylaxis Management

Background:

  • Systemic allergic reactions to insect stings affect 1-3% of children and adults.
  • Reactions vary by age, with children experiencing cutaneous signs and adults more prone to airway obstruction or hypotension.
  • Epinephrine auto-injectors are crucial for managing acute anaphylaxis in at-risk patients.

Purpose of the Study:

  • To review the epidemiology, diagnosis, and management of systemic allergic reactions to insect stings.
  • To highlight the efficacy and recommendations for venom immunotherapy.
  • To inform risk assessment for future sting reactions.

Main Methods:

  • Review of existing literature on insect sting allergies and anaphylaxis.

Related Experiment Videos

  • Analysis of risk factors for systemic reactions based on previous sting history.
  • Evaluation of diagnostic methods including venom-specific IgE testing.
  • Assessment of venom immunotherapy efficacy and duration.

    • Main Results:

    • Systemic sting reactions occur in 1% of children and 3% of adults, with differing clinical presentations.
    • Risk of future systemic reactions varies from 5-10% after large local reactions to 10-70% after previous systemic reactions.
    • Venom immunotherapy demonstrates 98% efficacy in preventing severe systemic reactions.

    Conclusions:

    • Venom immunotherapy is recommended for patients at risk of severe systemic reactions to insect stings.
    • Treatment involves regular injections for at least five years, potentially longer for high-risk individuals.
    • Prompt epinephrine administration is vital for acute anaphylaxis management.